Editorial Board

Editor-in-Chief
Charles J. Yeo, MD, FACS
Samuel D. Gross Professor and Chair
Department of Surgery
Thomas Jefferson University
1015 Walnut Street
Suite 620 Curtis Building
Philadelphia, PA 19107
Charles.Yeo@jefferson.edu

Associate Editors
Marc GH Besselink, MD, PhD
Academic Medical Center University
Amsterdam, Netherlands

Jonathan R. Brody, PhD
Thomas Jefferson University
Philadelphia, PA

Douglas Evans, MD
Medical College of Wisconsin
Milwaukee, WI

Theresa P. Yeo, PhD
Thomas Jefferson University
Philadelphia, PA

Editorial Board
Voichita Bar-Ad, MD
Thomas Jefferson University
Philadelphia, PA

Darren Carpizo, MD, PhD
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ

Carlos Chan, MD
National Institute of Medical Sciences and Nutrition
Tlalpan, Mexico

Cosimo Commiss, PhD
Sanford Burnham Prebys
Medical Discovery Institute
La Jolla, CA

Timothy Donahue, MD
University of California, Los Angeles
Los Angeles, CA

Ryan Fields, MD, FACS
Washington University School of Medicine
St. Louis, MO

S. Perwez Hussain, PhD
National Cancer Institute
Bethesda, MD

Thomas Kowalski, MD
Thomas Jefferson University
Philadelphia, PA

Ashok Kumar, MCh, MS, MBBS
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Uttar Pradesh, India

Harish Lavu, MD, FACS
Thomas Jefferson University
Philadelphia, PA

Jason Lewis, MD
Carolinas Healthcare System
Charlotte, NC

Keith D. Lillemoe, MD
Massachusetts General Hospital
Boston, MA

Anirban Maity, MBBS
The University of Texas MD Anderson Cancer Center
Houston, TX

Nipun Merchant, MD
University of Miami
Miami, FL

Johan Offerhaus, MD, PhD
University Medical Center Utrecht
Utrecht, Netherlands

Walter Park, MD, MS
Stanford University
Stanford, CA

Gloria M. Petersen, PhD
Mayo Clinic
Rochester, MN

Ashwin Sama, MD
Thomas Jefferson University
Philadelphia, PA

Richard Schulick, MD, MBA, FACS
University of Colorado, Denver
Denver, CO

Dong Shang, MD
Dalian Medical University
Dalian, China

Dietmar Tamandl, MD
Medical University of Vienna
Vienna, Austria

Jishu Wei, MD, PhD
Nanjing Medical University
Nanjing, China

Jordan M. Winter, MD
Thomas Jefferson University
Philadelphia, PA

Christopher Lee Wolfgang, MD, PhD, FACS
The Johns Hopkins University
School of Medicine
Baltimore, MD
Pancreatic cancer poses an enormous challenge to clinicians and cancer scientists. Despite efforts in the past 60 years, conventional treatments such as surgery, radiation, and chemotherapy are not consistently successful. Pancreatic cancer rates have risen steadily for several years, and the disease results in more than 300,000 deaths globally each year. It is currently the third most common cause of cancer deaths in the U.S., and has a five-year survival rate of less than 10%, when considering all cases. Pancreatic cancer is predicted to move to become the second leading cause of cancer death in the U.S. by 2020.

Surgery remains the predominate therapy for curative intention which may result in long-term survival and cure for some patients. However, small steps forward in the systemic therapy of pancreatic cancer have given rise to some optimism. In order to increase the medical and biomedical knowledge of pancreatic cancer, more research on disease development, adverse events, pharmacology, and family history is needed as well as novel treatments involving innovative technology, medical devices, or new therapeutics.

It is out of this need for more research that we launched *Journal of Pancreatic Cancer* in 2015 as the premier peer-reviewed journal for clinicians and cancer scientists to report research and advances. We hope that the Journal will promote interest in pancreatic cancer and encourage more research which can lead to significant therapeutic and prognostic progress.

We look forward to your contribution to the Journal.

**Charles J. Yeo, MD, FACS**
Editor-in-Chief
Aims & Scope

Journal of Pancreatic Cancer is the only peer reviewed journal focused solely on pancreatic cancer. The Journal is international, and open access, publishing articles covering the clinical, translational and basic science of malignancies of the pancreas and the peripancreatic region.

Journal of Pancreatic Cancer coverage includes:
- Pathological aspects
- Surgical techniques
- Innovative uses of novel technology or medical devices
- Genetic oncology
- Chemotherapy and drug therapy
- Radiation oncology
- Molecular targeted therapy
- Carcinogenesis
- Alternative and complementary treatments

The Journal provides a single open forum for communicating the advancement of science and treatments for pancreatic cancer. The Journal is relevant for surgical oncologists, pancreatologists, gastroenterologists, radiation oncologists, medical oncologists, endocrinologists, pathologists, palliative care specialists, epidemiologists, immunologists or cancer researchers investigating problems and treatments for pancreatic cancer. The Journal publishes scientific studies on the clinical immunological, pathological, biological and other aspects of the disease.

Benefits of Publishing in Journal of Pancreatic Cancer

Author benefits include:
- High visibility, immediate and unrestricted online access to published articles
- Rigorous and rapid peer review
- Easy compliance with open access mandates
- Authors retain copyright
- Highly indexed – citation tracking and inclusion in EMBASE/Exerpta Medica and Google Scholar
- Targeted email marketing
Instructions for Authors

Journal of Pancreatic Cancer is an international, open access journal covering the clinical, translational, and basic science of malignancies of the pancreas and the biliary region. Original research articles, review articles, narrative reviews, technical innovations, rapid communications, case reports, perspectives, and editorials covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, complementary and alternative treatment modalities and outcomes of pancreatic cancer are welcomed. The Journal considers high-quality clinical research letters for publication.

All manuscripts must be submitted through our online peer review submission system. Please read the entire Instructions for Authors to format your submission accordingly: www.liebertpub.com/manuscript/crpc

Open Access and Copyright

All articles published in Journal of Pancreatic Cancer are made freely and permanently accessible online upon publication without access or subscription charges, embargo periods, or user registration.

Upon submitting a manuscript for publication, the author(s) will agree to a Copyright and Open Access Licensing Agreement. Authors of articles published in the Journal will be the copyright holders and a Creative Commons CC-BY license will be applied.

For authors who are US government employees or are prevented from being copyright holders for similar reasons, Liebert Open Access can accommodate non-standard copyright. Please contact OpenAccess@liebertpub.com.

Article Publication Charges (APC)

Journal of Pancreatic Cancer is a fully open access journal. The cost of maintaining and publishing the Journal are covered by Article Publication Charges (APCs). Visit the Journal's Open Access Policy page for more information about the Journal's APC (www.liebertpub.com/CRPC). There are no color, submission, or page charges for this Journal. Submitting authors maybe entitled to a discount on the APC if their institution is a member of Liebert Author Advocacy Program (LAAP). Visit www.authoradvocacy.com to find out if your organization or institution is a member.

Permissions and Reprints

Journal of Pancreatic Cancer publishes articles under the Creative Commons Attribution license. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this Journal without requesting prior permission from the Publisher or the author.

Mary Ann Liebert, Inc. offers a reprint service for those who require professionally produced copies of a CC-BY licensed-article. Contact: reprints@liebertpub.com to obtain a quote. Please include the article DOI, title, number of reprint copies, and delivery destination.

Archiving and Preservation

Mary Ann Liebert, Inc. deposits and archives all publications in Portico for long-term digital preservation. Journal of Pancreatic Cancer is fully NIH-, HHMI-, and Wellcome Trust-compliant. Your article will be free online and will be easily searchable on Google, Google Scholar, and other search engines.
C-Reactive Protein/Albumin Ratio and Prognostic Nutritional Index Are Strong Prognostic Indicators of Survival in Resected Pancreatic Ductal Adenocarcinoma

Masahide Ikeguchi, Takehiko Hanaki, Kanenori Endo, Kazunori Suzuki, Seiichi Nakamura, Takashi Sawata, and Tetsu Shimizu

Abstract

Purpose: We evaluated the clinical importance, such as the occurrence of postoperative pancreatic fistula (POPF) or prognosis, of preoperative serum markers of chronic inflammation, nutrition, and immunity, as well as that of serum tumor markers after curative resection of pancreatic ductal adenocarcinomas (PDACs).

Methods: Between 2006 and 2015, 43 patients with PDACs underwent curative resection at Tottori Prefectural Central Hospital. We analyzed which preoperative indicators (i.e., C-reactive protein/albumin ratio [CAR], neutrophil/lymphocyte ratio [NLR], prognostic nutritional index [PNI], carcinoembryonic antigen [CEA], and carbohydrate antigen 19-9 [CA 19-9]) were the most relevant risk factors for occurrence of POPF and poor patient survival.

Results: POPF was detected in 8/43 (18.6%) patients. One patient died of pancreatic fistula at 2 months postoperatively. Among nine candidate factors (operative procedure, operation time, tumor stage, preoperative serum amylase, preoperative CAR, NLR, PNI, CEA, and CA 19-9), we did not identify any significant risk factor for the occurrence of POPF. The 5-year overall survival (OS) rate of the 43 patients was 22.4%, and the overall median survival time was 21 months. The multivariate OS analysis demonstrated that high CAR and low PNI were strong preoperative markers of poor prognosis independently of tumor stage.

Conclusions: Preoperative CAR and PNI are useful prognostic markers for patients with operable PDACs.

Keywords: C-reactive protein/albumin ratio; overall survival; pancreatic ductal adenocarcinoma; postoperative pancreatic fistula; prognostic nutritional index

Introduction

The prognosis of patients with pancreatic ductal adenocarcinomas (PDACs) is extremely poor. Even though curative resection is performed, many patients die of cancer recurrence within a few months. Yamamoto et al. reported that the median survival of 195 patients who underwent pancreatic resection was 27.1 months, and the 5-year actuarial survival rate was 34.5%. In addition, Sato et al. reported that in patients with resected PDACs in Japan, the estimated 5-year disease-specific survival rate was 23.1%, and the disease-free survival (DFS) rate was 16.8%. Moreover, it has been reported that after resection of the pancreas, postoperative complications occur very frequently. Anastomotic leakages between the pancreatic duct and the jejunum have been observed in 14–17% of patients after pancreaticoduodenectomy (PD). In addition, pancreatic fistula is frequently detected (16–26%) after distal pancreatectomy (DP). Such anastomotic leakages or pancreatic fistula are often fatal.
Recently, several studies found a strong correlation between poor survival and preoperative chronic inflammation, poor nutrition, and low immunity among patients with various cancers.\textsuperscript{12–14} Patient preoperative C-reactive protein/albumin ratio (CAR) has been used in combination with other parameters not only to diagnose chronic inflammation but also to assess the nutritional status of patients with cancer. Neutrophil/lymphocyte ratio (NLR) and prognostic nutritional index (PNI) are markers of chronic systemic inflammation and the patients’ immune status and nutritional condition.\textsuperscript{15,16} Also, serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) levels are known to be good progression indicators among patients with PDACs, including follow-up after resection of tumors.\textsuperscript{1,17}

In the present study, we evaluated the prognostic and clinical importance of serum markers of chronic inflammation, nutrition, and immunity combined with tumor markers of patients with PDACs.

**Patients and Methods**

**Patients**

Between 2006 and 2015, we enrolled 43 patients who were diagnosed with operable PDAC and underwent curative resection (no residual tumors macroscopically) at Tottori Prefectural Central Hospital. The average age of the 30 male and 13 female patients was 71.6 (range: 37–88) years. Clinical and pathological staging of PDACs was performed using the American Joint Committee on Cancer 6th edition tumor-node-metastasis (TNM) staging system for pancreatic cancer.\textsuperscript{18} All patients were followed up at Tottori Prefectural Central Hospital until the end of 2016. The mean follow-up period was 25.2 (range: 1–80) months. No patients received chemotherapy and radiation therapy before the operation. Informed consent for medical treatment and use of clinical data from medical records were obtained from all patients.

**Surgical procedure**

All patients underwent open laparotomy. According to the tumor location, we performed DP with splenectomy in 14 patients, subtotal stomach-preserving pancreaticoduodenectomy (SSPPD) in 24 patients, SSPPD combined with portal vein partial resection in 4 patients, and total pancreatectomy with splenectomy in 1 patient. After DP, we closed the proximal pancreas stump by suturing with 4-0 prolene in 12 patients and by linear stapler in 2 patients. Reconstruction after SSPPD or SSPPD with partial resection of the portal vein was performed by Child’s method (e.g., Braun’s anastomosis after pancreaticojejunostomy, choledochojejunostomy, and gastrojejunostomy).\textsuperscript{19} An internal short stent was placed across a pancreaticojejunostomy, but no stent was placed following choledochojejunostomy.

**Postoperative complications**

Postoperative complications were analyzed by patient clinical record data. The severity of postoperative complications was graded according to the Clavien–Dindo classification.\textsuperscript{20} In addition, a Clavien–Dindo score of III or higher was considered a major complication.

**Study design**

This study was a retrospective study. We recorded clinical parameters, including operation time, postoperative hospital stay, and occurrence of postoperative complications. Blood samples were taken from each patient routinely at the time of admission to our hospital. C-reactive protein, serum albumin, serum amylase, total lymphocyte count, and tumor markers, (including CEA and CA 19-9), were recorded. In addition, CAR, NLR, and PNI were calculated. The PNI was calculated using the following formula: \[ \text{PNI} = 10 \times \frac{\text{serum albumin concentration (g/dL)}}{\text{lymphocyte counts (no./mm}^3) } + 0.005 \times \text{lymphocyte counts (no./mm}^3) \]

In the present study, we evaluated the prognostic and clinical importance of serum markers of chronic inflammation, nutrition, and immunity combined with tumor markers of patients with PDACs.
probability tests. The Mann–Whitney U test was used to compare differences between two parameters with nonnormal distribution. Correlations between the parameters and occurrence of postoperative pancreatic fistula (POPF) were estimated using logistic-regression analysis. Long-term OS was calculated using the Kaplan–Meier method and the prognostic difference between the two groups was compared using the log-rank test. All data were analyzed by StatView software (Abacus Concepts, Inc., Berkeley, CA). 

\( p < 0.05 \) was regarded as indicating statistical significance.

**Results**

The clinical characteristics, operative procedure, operation time, postoperative complications, and postoperative hospital stay of all 43 patients with PDACs are presented in Table 1. Postoperative complications were detected in 34.9% of cases. POPF secondary to pancreatic juice leakage at the anastomotic site or at the pancreas stump was frequently detected (8/43, 18.6%). The mean length of postoperative hospital stay of the 15 patients with postoperative complications (61.4 days) was significantly longer than that of the 28 patients without postoperative complications (22.2 days, \( p < 0.001 \)). One patient died from postoperative peritonitis secondary to POPF 2 months postoperatively. Thus, the operative mortality and morbidity in our series were 2.3% and 34.9%, respectively.

The mean and median (range) of preoperative serum amylase, CAR, NLR, PNI, CEA, and CA 19-9 of all 43 patients with PDACs were as follows: serum amylase (111.7, 76, [42–399] U/L), CAR (0.11, 0.05, [0.01–0.57]), NLR (2.3, 2.2, [0.9–5.2]), PNI (47.7, 48.8, [29.4–63.4]), CEA (7.7, 4.5, [1.1–48.5] ng/mL), and CA 19-9 (369.7, 165, [1–2640] U/mL). According to the cutoff levels of the six parameters, abnormal levels of serum amylase, CAR, NLR, PNI, CEA, and CA 19-9 were detected in 11 (25.6%), 23 (53.5%), 18 (41.9%), 15 (34.9%), 19 (44.2%), and 31 (72.1%) of the 43 patients.

We analyzed factors that were thought to influence the occurrence of POPF. The nine candidate factors were operative procedure, operation time, tumor stage, preoperative serum amylase, preoperative CAR, NLR, PNI, CEA, and CA 19-9. We divided the patients into two subgroups (long and short) according to the median values of operation time, but we could not find any significant risk factor for the occurrence of POPF (data not shown).

The 5-year overall survival (OS) rate of the 43 patients was 22.4%, and the overall median survival time (MST) was 21 months. In addition, the 5-year DFS rate of the 43 patients was 9.1%, and the disease-free MST was 9 months. The correlation between the 10 candidate factors (operative procedure, operation time, tumor stage, occurrence of postoperative complications, preoperative serum amylase, preoperative CAR, NLR, PNI, CEA, and CA 19-9) and the overall MST and disease-free MST of 43 patients are shown in Table 2. We found that low preoperative PNI was important risk factor of poor survival in patients with PDACs and, we found that there was even no statistical significance, high preoperative CAR was also risk factor of poor survival. Figure 1 shows the OS curves of 28 patients with high PNI (solid line) and 15 patients with low PNI (dotted line). The 5-year OS of patients with low PNI (4%) was significantly poorer than that of patients with high PNI (35%, \( p = 0.001 \)). The multivariate analysis of OS showed that high CAR and low PNI were strong prognostic preoperative markers independently of tumor stage (Table 3). In addition, in multivariate analysis of DFS, we found that high CAR was a significant poor survival and recurrence preoperative marker (CAR: \( p = 0.018 \), odds ratio = 2.948, 95% confidence interval = 1.203–7.222), but low PNI was not (PNI: \( p = 0.124 \), odds ratio = 2.247, 95% confidence interval = 0.802–6.289).

**Discussion**

The incidences of severe POPF (Clavien–Dindo score of III or higher) were reported in 14–23% of patients after PD\textsuperscript{23} and in 10–30% of patients after DP\textsuperscript{24}.

**Table 1. Sample Characterizations (n = 43)**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years, mean, range)</td>
<td>71.6 (37–88)</td>
</tr>
<tr>
<td>Gender (male, %)</td>
<td>30 (69.8)</td>
</tr>
<tr>
<td>Operative procedures (%)</td>
<td>DP 14 (32.6)</td>
</tr>
<tr>
<td></td>
<td>SSPPD 24 (55.8)</td>
</tr>
<tr>
<td></td>
<td>SSPPD combined with portal vein partial resection 4 (9.3)</td>
</tr>
<tr>
<td></td>
<td>Total pancreatectomy with splenectomy 1 (2.3)</td>
</tr>
<tr>
<td>Operation time: min (mean, range)</td>
<td>324.7 (150–568)</td>
</tr>
<tr>
<td>Pathological tumor stages (%)</td>
<td>IA 3 (7)</td>
</tr>
<tr>
<td></td>
<td>IB 2 (4.7)</td>
</tr>
<tr>
<td></td>
<td>IIa 7 (16.3)</td>
</tr>
<tr>
<td></td>
<td>IIb 25 (58.1)</td>
</tr>
<tr>
<td></td>
<td>III 6 (14)</td>
</tr>
<tr>
<td>Postoperative complications</td>
<td>None 28</td>
</tr>
<tr>
<td></td>
<td>Yes (pancreatic fistula, passage disorder, others) 15 (8/3/4)</td>
</tr>
<tr>
<td>Postoperative hospital stay: day (mean, range)</td>
<td>35.9 (10–240)</td>
</tr>
</tbody>
</table>

DP, distal pancreatectomy; SSPPD, subtotal stomach-preserving pancreatoduodenectomy.
Also, some cases of POPF can be fatal. Soft pancreas or pancreatic thickness has been thought to be risk factors for occurrence of POPF.\textsuperscript{25,26} In our series, we found POPF in eight cases (18.6%, PD: 5/28, 17.9% and DP: 3/15, 20%), however, we found no significant correlation between POPF and poor survival.

The preoperative estimation of risk factors for poor prognosis of patients with PDACs has been studied. Pathological tumor stage was reported as a strong prognostic factor for patients with PDACs, but preoperative serum tumor markers, such as CA 19-9 and pancreatic cancer-associated antigen (DUPAN-2), were not.\textsuperscript{4} However, clinicians may change the treatment strategy for patients with PDACs based on strong preoperative prognostic markers. For patients who have poor prognosis based on preoperative prognostic markers, we recommend chemoradiotherapy before radical surgery, or perhaps even avoiding the surgical procedure altogether because of the high incidence of postoperative complications. In this study, we retrospectively analyzed the prognostic markers of patients with PDACs.

### Table 2. Univariate Survival Analyses of 43 Patients

<table>
<thead>
<tr>
<th>Prognostic marker</th>
<th>N</th>
<th>Overall MST (months)</th>
<th>p</th>
<th>Disease-free MST (months)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Operative procedures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DP or total pancreatectomy</td>
<td>15</td>
<td>29</td>
<td>0.266</td>
<td>12</td>
<td>0.614</td>
</tr>
<tr>
<td>SPPPD with or without portal vein resection</td>
<td>28</td>
<td>15</td>
<td></td>
<td>8</td>
<td></td>
</tr>
<tr>
<td><strong>Operation time</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long &gt;297 min</td>
<td>21</td>
<td>15</td>
<td>0.083</td>
<td>7</td>
<td>0.115</td>
</tr>
<tr>
<td>Short ≤297 min</td>
<td>22</td>
<td>28</td>
<td></td>
<td>13</td>
<td></td>
</tr>
<tr>
<td><strong>Tumor stages</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I and IIA</td>
<td>12</td>
<td>61</td>
<td>0.247</td>
<td>33</td>
<td>0.132</td>
</tr>
<tr>
<td>Stage II and III</td>
<td>31</td>
<td>18</td>
<td></td>
<td>8</td>
<td></td>
</tr>
<tr>
<td><strong>Postoperative complication</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>15</td>
<td>23</td>
<td>0.658</td>
<td>9</td>
<td>0.67</td>
</tr>
<tr>
<td>No</td>
<td>28</td>
<td>19</td>
<td></td>
<td>8</td>
<td></td>
</tr>
<tr>
<td><strong>Preoperative amylase level</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High &gt;125 U/L</td>
<td>11</td>
<td>15</td>
<td>0.481</td>
<td>10</td>
<td>0.994</td>
</tr>
<tr>
<td>Low ≤125 U/L</td>
<td>32</td>
<td>24</td>
<td></td>
<td>8</td>
<td></td>
</tr>
<tr>
<td><strong>Preoperative CAR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High &gt;0.04</td>
<td>23</td>
<td>19</td>
<td>0.06</td>
<td>6</td>
<td>0.085</td>
</tr>
<tr>
<td>Low ≤0.04</td>
<td>20</td>
<td>29</td>
<td></td>
<td>12</td>
<td></td>
</tr>
<tr>
<td><strong>Preoperative NLR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High &gt;2.5</td>
<td>18</td>
<td>19</td>
<td>0.248</td>
<td>8</td>
<td>0.311</td>
</tr>
<tr>
<td>Low ≤2.5</td>
<td>25</td>
<td>23</td>
<td></td>
<td>10</td>
<td></td>
</tr>
<tr>
<td><strong>Preoperative PNI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High &gt;44.7</td>
<td>28</td>
<td>26</td>
<td>0.001</td>
<td>13</td>
<td>0.003</td>
</tr>
<tr>
<td>Low ≤44.7</td>
<td>15</td>
<td>9</td>
<td></td>
<td>7</td>
<td></td>
</tr>
<tr>
<td><strong>Preoperative CEA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High &gt;5 ng/mL</td>
<td>19</td>
<td>24</td>
<td>0.89</td>
<td>9</td>
<td>0.485</td>
</tr>
<tr>
<td>Low ≤5 ng/mL</td>
<td>24</td>
<td>21</td>
<td></td>
<td>10</td>
<td></td>
</tr>
<tr>
<td><strong>Preoperative CA 19-9</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High &gt;37 U/mL</td>
<td>31</td>
<td>15</td>
<td>0.207</td>
<td>8</td>
<td>0.13</td>
</tr>
<tr>
<td>Low ≤37 U/mL</td>
<td>12</td>
<td>12</td>
<td></td>
<td>23</td>
<td></td>
</tr>
</tbody>
</table>

CA 19-9, carbohydrate antigen 19-9; CAR, C-reactive protein/albumin ratio; CEA, carcinoembryonic antigen; NLR, neutrophil/lymphocyte ratio; PNI, prognostic nutritional index.

**FIG. 1.** Overall survival curves of patients. Twenty-eight patients with high PNI (solid line) had significantly better survival than 15 patients with low PNI (dotted line, p = 0.001). PNI, prognostic nutritional index.
in various cancers. 

In PDACs, Geng et al. reported a significant correlation between low PNI and poor survival. Moreover, a significant correlation between nutrition, the nutritional status, and immunological status, which may be useful in pre-operative prognosis in PDACs. This index is designed to assess nutritional status, determined by incorporating albumin and absolute lymphocyte count, which are measured routinely in clinical practice. This index is designed to assess nutritional and immunological status, which may be useful in predicting prognosis. Moreover, a significant correlation between low PNI and poor survival has been reported in various cancers. 

In PDACs, Geng et al. reported that low PNI correlated significantly with shorter OS in patients with advanced pancreatic cancer. In this study, multivariate analysis identified PNI as an independent prognostic factor for OS. Thus, we recommended the preoperative assessment of CAR and PNI before planning the treatment strategies for patients with PDACs. Also, it may be possible that improvement of nutrition before surgery may improve patient’s post-operative prognosis in PDACs.

### Table 3. Multivariate Overall Survival Analysis of 43 Patients

<table>
<thead>
<tr>
<th>Outcome</th>
<th>p</th>
<th>Odds ratio</th>
<th>95% Confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operative procedures</td>
<td>0.995</td>
<td>0.996</td>
<td>0.325–3.053</td>
</tr>
<tr>
<td>DP or total pancreatectomy vs. SSSPD with or without portal vein resection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operation time</td>
<td>0.062</td>
<td>2.625</td>
<td>0.954–7.194</td>
</tr>
<tr>
<td>Long &gt;297 min vs. short ≤297 min</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor stages</td>
<td>0.148</td>
<td>2.1</td>
<td>0.768–5.747</td>
</tr>
<tr>
<td>Stage I and IIA vs. Stage IIB and III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postoperative complication</td>
<td>0.083</td>
<td>0.419</td>
<td>0.157–1.118</td>
</tr>
<tr>
<td>Yes vs. no</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative amylase level</td>
<td>0.4</td>
<td>0.617</td>
<td>0.201–1.899</td>
</tr>
<tr>
<td>High &gt;125 U/L vs. low ≤125 U/L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative CAR</td>
<td>0.025</td>
<td>2.895</td>
<td>1.142–7.339</td>
</tr>
<tr>
<td>High &gt;0.04 vs. low ≤0.04</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative NLR</td>
<td>0.103</td>
<td>0.373</td>
<td>0.114–1.22</td>
</tr>
<tr>
<td>High &gt;2.5 vs. low ≤2.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative PNI</td>
<td>0.003</td>
<td>6.803</td>
<td>1.919–24.39</td>
</tr>
<tr>
<td>High &gt;44.7 vs. low ≤44.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative CEA</td>
<td>0.829</td>
<td>0.914</td>
<td>0.403–2.072</td>
</tr>
<tr>
<td>High &gt;5 ng/mL vs. low ≤5 ng/mL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative CA 19-9</td>
<td>0.746</td>
<td>1.231</td>
<td>0.35–4.335</td>
</tr>
<tr>
<td>High &gt;37 U/mL vs. low ≤37 U/mL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Conclusion

High preoperative CAR and low PNI levels strongly correlated with poor survival in patients with PDACs. These markers should be assessed when selecting the treatment strategies for patients with PDACs.

### Acknowledgment

We specially thank Dr. Hiroaki Saito (Department of Surgery, Division of Surgical Oncology, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan) for analyzing the ROC curves.

### Author Disclosure Statement

No competing financial interests exist.

### References


Abbreviations Used

CA 19-9 = carbohydrate antigen 19-9
CAR = C-reactive protein/albumin ratio
CEA = carcinoembryonic antigen
DFS = disease-free survival
DP = distal pancreatectomy
MST = median survival time
NLR = neutrophil/lymphocyte ratio
OS = overall survival
PD = pancreateicoduodenectomy
PDAC = pancreatic ductal adenocarcinoma
PNI = prognostic nutritional index
POPF = postoperative pancreatic fistula
ROC = receiver operating characteristic
SSPPD = stomach-preserving pancreateicoduodenectomy
Ready to Submit?

➢ Review our complete manuscript preparation instructions:
  liebertpub.com/manuscript/pancan

➢ Submit your manuscript via our online submission and peer review system:
  mc.manuscriptcentral.com/pancan

Please feel free to contact us with any questions you may have:

Editorial Contact
Dr. Charles J. Yeo
Samuel D. Gross Professor and Chair
Department of Surgery
Thomas Jefferson University
Jefferson Medical College
1015 Walnut Street
Suite 620 Curtis Building
Philadelphia, PA 19107
Charles.Yeo@jefferson.edu

Publisher Contact
Sophie Mohin
Managing Editor
Mary Ann Liebert, Inc., publishers
140 Huguenot Street, 3rd Floor
New Rochelle, NY 10801
smohin@liebertpub.com

Sign up for free email alerts, including calls for papers, at
liebertpub.com/pancan/connect

Liebert Open Access

www.liebertpub.com/crpc
www.liebertopenaccess.com

Mary Ann Liebert, Inc., publishers